✦ LIBER ✦

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

✍ Scribed by Warso, M A; Richards, J M; Mehta, D; Christov, K; Schaeffer, C; Rae Bressler, L; Yamada, T; Majumdar, D; Kennedy, S A; Beattie, C W; Das Gupta, T K

Book ID: 120518615
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 748 KB
Volume: 108
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.2013.74

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of LY2584702 tosylate, a

A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours

✍ Tolcher, Anthony; Goldman, Jonathan; Patnaik, Amita; Papadopoulos, Kyriakos P.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 769 KB

A first in human phase I study of the pr

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

✍ Gallerani, Elisa; Zucchetti, Massimo; Brunelli, Dario; Marangon, Elena; Noberasc 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 365 KB

A Phase I First-in-Human Trial of Bardox

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

✍ Hong, D. S.; Kurzrock, R.; Supko, J. G.; He, X.; Naing, A.; Wheler, J.; Lawrence 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 753 KB

365 First-in-human, safety, pharmacodyna

365 First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumour

✍ J.C. Soria; U. Banerji; R. Bahleda; M. Martinez Garcia; S. Dolly; L. Lee; R. Rue 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 63 KB

A phase I trial of ispinesib, a kinesin

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

✍ Blagden, S P; Molife, L R; Seebaran, A; Payne, M; Reid, A H M; Protheroe, A S; V 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 150 KB

364 The first-in-human, first-in-class s

364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer

✍ T. Shimizu; A.W. Tolcher; P. LoRusso; K. Papadopoulos; A. Patnaik; L. Smith; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB